{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:02:49Z","timestamp":1789506169359,"version":"build-2803163510"},"reference-count":169,"publisher":"The Endocrine Society","issue":"6","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100012264","name":"NIH","doi-asserted-by":"publisher","award":["CA248048"],"award-info":[{"award-number":["CA248048"]}],"id":[{"id":"10.13039\/501100012264","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014039","name":"DOD Prostate Cancer Research Program","doi-asserted-by":"publisher","award":["PC230591"],"award-info":[{"award-number":["PC230591"]}],"id":[{"id":"10.13039\/100014039","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Metastatic prostate cancer (PCa) remains a major cause of cancer deaths in Western men. Although androgen deprivation therapy (ADT) initially induces remissions, patients ultimately develop incurable castration resistance, underscoring the need for alternative or complementary therapeutic strategies. Protein\u2013protein interactions (PPIs) play a central role in oncogenic signaling, and aberrant protein dimerization is increasingly recognized as a critical driver of PCa progression and therapeutic resistance. Both homodimeric and heterodimeric protein complexes regulate key pathways involved in androgen receptor signaling, transcriptional control, and adaptation to tumor microenvironmental stress. Here, we review current evidence for oncogenic dimerization events in PCa and discuss their relevance for PCa progression. We highlight how similar dimeric interactions have been successfully targeted for therapy in other malignancies, with several strategies advancing to late-stage clinical trials or regulatory approval, underscoring their translational potential for PCa. We summarize approaches to modulate dimerization and highlight their mechanisms of action, therapeutic advantages, and inherent limitations. By combining pre-clinical and clinical findings with conceptual therapeutic frameworks, this review outlines the opportunities and limitations of targeting protein dimerization in PCa. Collectively, we propose that rational disruption of oncogenic homo- and heterodimers represents an underexplored yet promising therapeutic strategy that could complement existing treatments and help overcome resistance in advanced PCa.<\/jats:p>","DOI":"10.1210\/endocr\/bqag056","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:28:25Z","timestamp":1777638505000},"source":"Crossref","is-referenced-by-count":1,"title":["Breaking the bonds: targeting protein dimerization for prostate cancer therapy"],"prefix":"10.1210","volume":"167","author":[{"given":"Nidhi","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Cancer Sciences, Cleveland Clinic Research, Cleveland Clinic , Cleveland, OH 44195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9137-5083","authenticated-orcid":false,"given":"Hannelore V","family":"Heemers","sequence":"additional","affiliation":[{"name":"Department of Cancer Sciences, Cleveland Clinic Research, Cleveland Clinic , Cleveland, OH 44195, USA"},{"name":"Cleveland Clinic Lerner College of Medicine, Case Western Reserve University , Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"issue":"6","key":"2026052423113505700_bqag056-B1","first-page":"485","article-title":"Prostate cancer statistics, 2025","volume":"75","author":"Kratzer","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2026052423113505700_bqag056-B2","first-page":"e70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J Clin"},{"key":"2026052423113505700_bqag056-B3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.diff.2018.08.005","article-title":"Development of the human prostate","volume":"103","author":"Cunha","year":"2018","journal-title":"Differentiation"},{"issue":"11","key":"2026052423113505700_bqag056-B4","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/ng.3419","article-title":"The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis","volume":"47","author":"Pomerantz","year":"2015","journal-title":"Nat Genet"},{"issue":"26","key":"2026052423113505700_bqag056-B5","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1200\/JCO.23.00433","article-title":"Targeting the androgen signaling axis in prostate cancer","volume":"41","author":"Dai","year":"2023","journal-title":"J Clin Oncol"},{"issue":"41","key":"2026052423113505700_bqag056-B6","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1038\/s41388-025-03573-z","article-title":"Evolving roles for the androgen receptor and its protein interactome in castration-resistant prostate cancer","volume":"44","author":"Chukhu","year":"2025","journal-title":"Oncogene"},{"issue":"8","key":"2026052423113505700_bqag056-B7","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"2026052423113505700_bqag056-B8","doi-asserted-by":"crossref","first-page":"469","DOI":"10.6004\/jnccn.2025.0052","article-title":"Prostate cancer, version 3.2026, NCCN clinical practice guidelines in oncology","volume":"23","author":"Spratt","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"2026052423113505700_bqag056-B9","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41585-021-00490-0","article-title":"Molecular events in neuroendocrine prostate cancer development","volume":"18","author":"Wang","year":"2021","journal-title":"Nat Rev Urol"},{"issue":"1","key":"2026052423113505700_bqag056-B10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41392-024-02036-3","article-title":"New insights into protein-protein interaction modulators in drug discovery and therapeutic advance","volume":"9","author":"Nada","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026052423113505700_bqag056-B11","doi-asserted-by":"crossref","first-page":"107544","DOI":"10.1016\/j.phrs.2024.107544","article-title":"Targeting protein-protein interactions in drug discovery: modulators approved or in clinical trials for cancer treatment","volume":"211","author":"Camps-Fajol","year":"2025","journal-title":"Pharmacol Res"},{"issue":"9","key":"2026052423113505700_bqag056-B12","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/pro.2736","article-title":"Linking structural features of protein complexes and biological function","volume":"24","author":"Sowmya","year":"2015","journal-title":"Protein Sci"},{"key":"2026052423113505700_bqag056-B13","first-page":"1","article-title":"Homo- and heterodimerization of proteins in cell signaling: inhibition and drug design","volume":"111","author":"Singh","year":"2018","journal-title":"Adv Protein Chem Struct Biol"},{"issue":"14","key":"2026052423113505700_bqag056-B14","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1073\/pnas.0401123101","article-title":"Structural basis of androgen receptor binding to selective androgen response elements","volume":"101","author":"Shaffer","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2026052423113505700_bqag056-B15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1146\/annurev.biophys.29.1.105","article-title":"Structural symmetry and protein function","volume":"29","author":"Goodsell","year":"2000","journal-title":"Annu Rev Biophys Biomol Struct"},{"issue":"1","key":"2026052423113505700_bqag056-B16","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1186\/s12967-024-05445-8","article-title":"HER3 receptor and its role in the therapeutic management of metastatic breast cancer","volume":"22","author":"Zhu","year":"2024","journal-title":"J Transl Med"},{"issue":"7","key":"2026052423113505700_bqag056-B17","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3390\/genes15070903","article-title":"A comprehensive review of HER2 in cancer biology and therapeutics","volume":"15","author":"Cheng","year":"2024","journal-title":"Genes (Basel)"},{"key":"2026052423113505700_bqag056-B18","doi-asserted-by":"crossref","first-page":"114964","DOI":"10.1016\/j.bcp.2022.114964","article-title":"Bcr-Abl drives the formation of Hsp70\/Bim PPI to stabilize oncogenic clients and prevent cells from undergoing apoptosis","volume":"198","author":"Zhang","year":"2022","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"2026052423113505700_bqag056-B19","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1080\/07391102.2012.687525","article-title":"Inhibition of protein-protein interaction of HER2-EGFR and HER2-HER3 by a rationally designed peptidomimetic","volume":"30","author":"Banappagari","year":"2012","journal-title":"J Biomol Struct Dyn"},{"issue":"1","key":"2026052423113505700_bqag056-B20","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3390\/ijms20010120","article-title":"Therapeutic inhibition of Myc in cancer. Structural bases and computer-aided drug discovery approaches","volume":"20","author":"Carabet","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2026052423113505700_bqag056-B21","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13045-020-00850-0","article-title":"The design and development of covalent protein-protein interaction inhibitors for cancer treatment","volume":"13","author":"Cheng","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"7126","key":"2026052423113505700_bqag056-B22","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature05474","article-title":"Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3","volume":"445","author":"Sergina","year":"2007","journal-title":"Nature"},{"issue":"6","key":"2026052423113505700_bqag056-B23","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1073\/pnas.0510948103","article-title":"Protein-protein interactions for cancer therapy","volume":"103","author":"Harris","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026052423113505700_bqag056-B24","doi-asserted-by":"crossref","first-page":"682675","DOI":"10.3389\/fchem.2021.682675","article-title":"Rational design of peptide-based inhibitors disrupting protein-protein interactions","volume":"9","author":"Wang","year":"2021","journal-title":"Front Chem"},{"issue":"3","key":"2026052423113505700_bqag056-B25","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3390\/ijms23031550","article-title":"Challenges in discovering drugs that target the protein-protein interactions of disordered proteins","volume":"23","author":"Olah","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2026052423113505700_bqag056-B26","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/mt.2015.214","article-title":"Modulation of protein-protein interactions for the development of novel therapeutics","volume":"24","author":"Petta","year":"2016","journal-title":"Mol Ther"},{"issue":"1","key":"2026052423113505700_bqag056-B27","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41392-020-00315-3","article-title":"Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials","volume":"5","author":"Lu","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2026052423113505700_bqag056-B28","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41392-023-01589-z","article-title":"Recent advances in targeting the \u201cundruggable\u201d proteins: from drug discovery to clinical trials","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2026052423113505700_bqag056-B29","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cbpa.2018.06.004","article-title":"Inhibitors of protein-protein interactions (PPIs): an analysis of scaffold choices and buried surface area","volume":"44","author":"Ran","year":"2018","journal-title":"Curr Opin Chem Biol"},{"issue":"2","key":"2026052423113505700_bqag056-B30","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ccell.2020.07.007","article-title":"Microenvironment-mediated resistance to anti-androgen therapy","volume":"38","author":"Orme","year":"2020","journal-title":"Cancer Cell"},{"key":"2026052423113505700_bqag056-B31","first-page":"14","article-title":"HER3-targeted therapy: the mechanism of drug resistance and the development of anticancer drugs","volume":"7","author":"Zeng","year":"2024","journal-title":"Cancer Drug Resist"},{"issue":"4","key":"2026052423113505700_bqag056-B32","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1535-6108(04)00083-2","article-title":"Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex","volume":"5","author":"Franklin","year":"2004","journal-title":"Cancer Cell"},{"key":"2026052423113505700_bqag056-B33","first-page":"65","article-title":"Role of pertuzumab in the treatment of HER2-positive breast cancer","volume":"4","author":"Hubalek","year":"2012","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"9","key":"2026052423113505700_bqag056-B34","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nrd3538","article-title":"Trial watch: ERBB2 dimerization inhibitor meets end point in breast cancer trial","volume":"10","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"2026052423113505700_bqag056-B35","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1634\/theoncologist.2008-0816","article-title":"FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2","volume":"13","author":"Ryan","year":"2008","journal-title":"Oncologist"},{"issue":"1","key":"2026052423113505700_bqag056-B36","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.urolonc.2010.09.018","article-title":"A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer","volume":"31","author":"Whang","year":"2013","journal-title":"Urol Oncol"},{"issue":"1","key":"2026052423113505700_bqag056-B37","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s00018-024-05540-5","article-title":"Amiloride sensitizes prostate cancer cells to the reversible tyrosine kinase inhibitor lapatinib by modulating Erbb3 subcellular localization","volume":"82","author":"Jathal","year":"2024","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"2026052423113505700_bqag056-B38","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3390\/cancers16030601","article-title":"Novel approaches with HIF-2alpha targeted therapies in metastatic renal cell carcinoma","volume":"16","author":"Nguyen","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026052423113505700_bqag056-B39","doi-asserted-by":"crossref","first-page":"1533033821990010","DOI":"10.1177\/1533033821990010","article-title":"Hypoxia-inducible factor 2a expression is positively correlated with gleason score in prostate cancer","volume":"20","author":"Pavlakis","year":"2021","journal-title":"Technol Cancer Res Treat"},{"issue":"10","key":"2026052423113505700_bqag056-B40","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1158\/0008-5472.CAN-05-1341","article-title":"Hypoxia increases androgen receptor activity in prostate cancer cells","volume":"66","author":"Park","year":"2006","journal-title":"Cancer Res"},{"issue":"21","key":"2026052423113505700_bqag056-B41","doi-asserted-by":"crossref","first-page":"7658","DOI":"10.1158\/1078-0432.CCR-05-0460","article-title":"The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer","volume":"11","author":"Boddy","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2026052423113505700_bqag056-B42","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.1038\/s41467-018-07411-7","article-title":"Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen\/AR-targeted therapy","volume":"9","author":"Geng","year":"2018","journal-title":"Nat Commun"},{"issue":"6","key":"2026052423113505700_bqag056-B43","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1124\/mol.114.097477","article-title":"Dual targeting of the androgen receptor and hypoxia-inducible factor 1alpha pathways synergistically inhibits castration-resistant prostate cancer cells","volume":"87","author":"Fernandez","year":"2015","journal-title":"Mol Pharmacol"},{"issue":"1","key":"2026052423113505700_bqag056-B44","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/21541264.2024.2417475","article-title":"Hypoxia-inducible transcription factors: architects of tumorigenesis and targets for anticancer drug discovery","volume":"16","author":"McDermott","year":"2025","journal-title":"Transcription"},{"issue":"21","key":"2026052423113505700_bqag056-B45","doi-asserted-by":"crossref","first-page":"9691","DOI":"10.1021\/acs.jmedchem.8b01196","article-title":"Design and activity of specific hypoxia-inducible factor-2alpha (HIF-2alpha) inhibitors for the treatment of clear cell renal cell carcinoma: discovery of clinical candidate (S)-3-((2,2-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385)","volume":"61","author":"Wehn","year":"2018","journal-title":"J Med Chem"},{"issue":"6","key":"2026052423113505700_bqag056-B46","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/molpharm.122.000525","article-title":"Structural basis for the allosteric inhibition of hypoxia-inducible factor (HIF)-2 by belzutifan","volume":"102","author":"Ren","year":"2022","journal-title":"Mol Pharmacol"},{"issue":"13","key":"2026052423113505700_bqag056-B47","doi-asserted-by":"crossref","first-page":"8877","DOI":"10.1021\/jacs.3c10508","article-title":"Identification and development of cyclic peptide inhibitors of hypoxia inducible factors 1 and 2 that disrupt hypoxia-response signaling in cancer cells","volume":"146","author":"Ball","year":"2024","journal-title":"J Am Chem Soc"},{"issue":"6","key":"2026052423113505700_bqag056-B48","doi-asserted-by":"crossref","first-page":"a014241","DOI":"10.1101\/cshperspect.a014241","article-title":"MYC activation is a hallmark of cancer initiation and maintenance","volume":"4","author":"Gabay","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"40","key":"2026052423113505700_bqag056-B49","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.1038\/sj.onc.1206641","article-title":"Low molecular weight inhibitors of Myc-Max interaction and function","volume":"22","author":"Yin","year":"2003","journal-title":"Oncogene"},{"issue":"4","key":"2026052423113505700_bqag056-B50","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00280-008-0774-y","article-title":"Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice","volume":"63","author":"Guo","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"2026052423113505700_bqag056-B51","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1073\/pnas.062036999","article-title":"Small-molecule antagonists of Myc\/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts","volume":"99","author":"Berg","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"21","key":"2026052423113505700_bqag056-B52","doi-asserted-by":"crossref","first-page":"6038","DOI":"10.1016\/j.bmcl.2009.09.044","article-title":"Small molecule inhibitors of Myc\/Max dimerization and Myc-induced cell transformation","volume":"19","author":"Shi","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"issue":"12","key":"2026052423113505700_bqag056-B53","doi-asserted-by":"crossref","first-page":"dju320","DOI":"10.1093\/jnci\/dju320","article-title":"Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer","volume":"106","author":"Stellas","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"2026052423113505700_bqag056-B54","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41417-022-00455-4","article-title":"3JC48-3 (methyl 4\u2032-methyl-5-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-[1,1\u2032-biphenyl]-3-carboxylate): a novel MYC\/MAX dimerization inhibitor reduces prostate cancer growth","volume":"29","author":"Shukla","year":"2022","journal-title":"Cancer Gene Ther"},{"issue":"7","key":"2026052423113505700_bqag056-B55","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.21873\/anticanres.17672","article-title":"A novel three small molecule inhibitor combination therapy for prostate cancer","volume":"45","author":"Demir","year":"2025","journal-title":"Anticancer Res"},{"issue":"5","key":"2026052423113505700_bqag056-B56","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.3390\/ijms23052588","article-title":"Development of VPC-70619, a small-molecule N-Myc inhibitor as a potential therapy for neuroendocrine prostate cancer","volume":"23","author":"Ton","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"7","key":"2026052423113505700_bqag056-B57","doi-asserted-by":"crossref","first-page":"e22284","DOI":"10.1371\/journal.pone.0022284","article-title":"The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy","volume":"6","author":"Savino","year":"2011","journal-title":"PLoS One"},{"key":"2026052423113505700_bqag056-B58","author":"Awah"},{"issue":"3","key":"2026052423113505700_bqag056-B59","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41591-024-02805-1","article-title":"MYC targeting by OMO-103 in solid tumors: a phase 1 trial","volume":"30","author":"Garralda","year":"2024","journal-title":"Nat Med"},{"issue":"2","key":"2026052423113505700_bqag056-B60","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/ng1293","article-title":"Dynamics of the p53-Mdm2 feedback loop in individual cells","volume":"36","author":"Lahav","year":"2004","journal-title":"Nat Genet"},{"issue":"7471","key":"2026052423113505700_bqag056-B61","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"issue":"6","key":"2026052423113505700_bqag056-B62","doi-asserted-by":"crossref","first-page":"a026336","DOI":"10.1101\/cshperspect.a026336","article-title":"The role of MDM2 amplification and overexpression in tumorigenesis","volume":"6","author":"Oliner","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"15","key":"2026052423113505700_bqag056-B63","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1093\/nar\/26.15.3453","article-title":"The MDM2 gene amplification database","volume":"26","author":"Momand","year":"1998","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2026052423113505700_bqag056-B64","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1146\/annurev-biochem-060815-014710","article-title":"The p53 pathway: origins, inactivation in cancer, and emerging therapeutic approaches","volume":"85","author":"Joerger","year":"2016","journal-title":"Annu Rev Biochem"},{"issue":"17","key":"2026052423113505700_bqag056-B65","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/jnci\/86.17.1297","article-title":"MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status","volume":"86","author":"Florenes","year":"1994","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl_10)","key":"2026052423113505700_bqag056-B66","first-page":"2231","article-title":"P53 mutation and MDM2 amplification in human soft tissue sarcomas","volume":"53","author":"Leach","year":"1993","journal-title":"Cancer Res"},{"issue":"9","key":"2026052423113505700_bqag056-B67","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.3390\/ijms23095005","article-title":"Therapeutics targeting p53-MDM2 interaction to induce cancer cell death","volume":"23","author":"Koo","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"11","key":"2026052423113505700_bqag056-B68","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1038\/s41375-020-0949-z","article-title":"MDM2 inhibition: an important step forward in cancer therapy","volume":"34","author":"Konopleva","year":"2020","journal-title":"Leukemia"},{"issue":"5","key":"2026052423113505700_bqag056-B69","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/cncr.21261","article-title":"MDM2 as a predictor of prostate carcinoma outcome: an analysis of radiation therapy oncology group protocol 8610","volume":"104","author":"Khor","year":"2005","journal-title":"Cancer"},{"issue":"5","key":"2026052423113505700_bqag056-B70","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/modpathol.3880330","article-title":"Abnormal expression of MDM2 in prostate carcinoma","volume":"14","author":"Leite","year":"2001","journal-title":"Mod Pathol"},{"issue":"7406","key":"2026052423113505700_bqag056-B71","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature11125","article-title":"The mutational landscape of lethal castration-resistant prostate cancer","volume":"487","author":"Grasso","year":"2012","journal-title":"Nature"},{"key":"2026052423113505700_bqag056-B72","doi-asserted-by":"crossref","first-page":"871259","DOI":"10.3389\/fphar.2022.871259","article-title":"Novel MDM2 inhibitor XR-2 exerts potent anti-tumor efficacy and overcomes enzalutamide resistance in prostate cancer","volume":"13","author":"Wu","year":"2022","journal-title":"Front Pharmacol"},{"issue":"1","key":"2026052423113505700_bqag056-B73","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1476-4598-10-49","article-title":"MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer","volume":"10","author":"Tovar","year":"2011","journal-title":"Mol Cancer"},{"issue":"4","key":"2026052423113505700_bqag056-B74","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.neo.2016.01.006","article-title":"MDM2 inhibition sensitizes prostate cancer cells to androgen ablation and radiotherapy in a p53-dependent manner","volume":"18","author":"Feng","year":"2016","journal-title":"Neoplasia"},{"issue":"9","key":"2026052423113505700_bqag056-B75","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.22.01285","article-title":"A first-in-human phase I study of milademetan, an MDM2 inhibitor, in patients with advanced liposarcoma, solid tumors, or lymphomas","volume":"41","author":"Gounder","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"2026052423113505700_bqag056-B76","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1182\/blood.2022016362","article-title":"Venetoclax and idasanutlin in relapsed\/refractory AML: a nonrandomized, open-label phase 1b trial","volume":"141","author":"Daver","year":"2023","journal-title":"Blood"},{"issue":"4","key":"2026052423113505700_bqag056-B77","first-page":"53","article-title":"MDM2 inhibition marches on across cancer settings","volume":"12","author":"Negr\u00e3o","year":"2023","journal-title":"Target Oncol"},{"issue":"3","key":"2026052423113505700_bqag056-B78","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","article-title":"Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins","volume":"20","author":"Singh","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"2026052423113505700_bqag056-B79","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41392-025-02176-0","article-title":"The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy","volume":"10","author":"Vogler","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"2026052423113505700_bqag056-B80","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/cdd.2008.37","article-title":"Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?","volume":"15","author":"Labi","year":"2008","journal-title":"Cell Death Differ"},{"issue":"1","key":"2026052423113505700_bqag056-B81","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1038\/s41467-018-06067-7","article-title":"Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses","volume":"9","author":"Li","year":"2018","journal-title":"Nat Commun"},{"issue":"12","key":"2026052423113505700_bqag056-B82","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1038\/sj.onc.1207326","article-title":"Androgens repress Bcl-2 expression via activation of the retinoblastoma (RB) protein in prostate cancer cells","volume":"23","author":"Huang","year":"2004","journal-title":"Oncogene"},{"issue":"6","key":"2026052423113505700_bqag056-B83","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/cr.2007.12","article-title":"Up-regulation of Bcl-2 is required for the progression of prostate cancer cells from an androgen-dependent to an androgen-independent growth stage","volume":"17","author":"Lin","year":"2007","journal-title":"Cell Res"},{"issue":"24","key":"2026052423113505700_bqag056-B84","first-page":"6940","article-title":"Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer","volume":"52","author":"McDonnell","year":"1992","journal-title":"Cancer Res"},{"issue":"18","key":"2026052423113505700_bqag056-B85","doi-asserted-by":"crossref","first-page":"e179998","DOI":"10.1172\/JCI179998","article-title":"BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity","volume":"134","author":"Westaby","year":"2024","journal-title":"J Clin Invest"},{"issue":"24","key":"2026052423113505700_bqag056-B86","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"4","key":"2026052423113505700_bqag056-B87","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with Venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"2026052423113505700_bqag056-B88","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00280-025-04840-2","article-title":"Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer","volume":"95","author":"Perimbeti","year":"2025","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"2026052423113505700_bqag056-B89","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1158\/0008-5472.CAN-21-3565","article-title":"A genome-wide CRISPR activation screen identifies PRRX2 as a regulator of enzalutamide resistance in prostate cancer","volume":"82","author":"Rodriguez","year":"2022","journal-title":"Cancer Res"},{"issue":"9","key":"2026052423113505700_bqag056-B90","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res"},{"issue":"18","key":"2026052423113505700_bqag056-B91","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1182\/blood.2023019706","article-title":"Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy","volume":"143","author":"Liu","year":"2024","journal-title":"Blood"},{"issue":"24","key":"2026052423113505700_bqag056-B92","doi-asserted-by":"crossref","first-page":"5455","DOI":"10.1158\/1078-0432.CCR-21-4037","article-title":"Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy","volume":"28","author":"Deng","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"Suppl_16","key":"2026052423113505700_bqag056-B93","doi-asserted-by":"crossref","first-page":"TPS7071","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS7071","article-title":"Phase 1 study of LP-108 as monotherapy and in combination with azacitidine in patients with relapsed or refractory myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML)","volume":"40","author":"Walker","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026052423113505700_bqag056-B94","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3389\/fphar.2017.00557","article-title":"BH3 mimetics for the treatment of prostate cancer","volume":"8","author":"Wolf","year":"2017","journal-title":"Front Pharmacol"},{"issue":"6455","key":"2026052423113505700_bqag056-B95","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/366580a0","article-title":"Polypeptide signalling to the nucleus through tyrosine phosphorylation of Jak and stat proteins","volume":"366","author":"Shuai","year":"1993","journal-title":"Nature"},{"issue":"12","key":"2026052423113505700_bqag056-B96","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0962-8924(01)02154-7","article-title":"SH2 domains, interaction modules and cellular wiring","volume":"11","author":"Pawson","year":"2001","journal-title":"Trends Cell Biol"},{"issue":"3","key":"2026052423113505700_bqag056-B97","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3390\/cancers16030492","article-title":"Exploring novel frontiers: leveraging STAT3 signaling for advanced cancer therapeutics","volume":"16","author":"Adesoye","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2026052423113505700_bqag056-B98","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/cr.2008.18","article-title":"STAT3 as a target for inducing apoptosis in solid and hematological tumors","volume":"18","author":"Al Zaid Siddiquee","year":"2008","journal-title":"Cell Res"},{"issue":"3","key":"2026052423113505700_bqag056-B99","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.urology.2005.03.066","article-title":"Clinical and pathologic significance of activation of signal transducer and activator of transcription 3 in prostate cancer","volume":"66","author":"Horinaga","year":"2005","journal-title":"Urology"},{"issue":"6","key":"2026052423113505700_bqag056-B100","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.2353\/ajpath.2008.071054","article-title":"Stat3 promotes metastatic progression of prostate cancer","volume":"172","author":"Abdulghani","year":"2008","journal-title":"Am J Pathol"},{"issue":"3","key":"2026052423113505700_bqag056-B101","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.eururo.2016.06.018","article-title":"Expression of STAT3 in prostate cancer metastases","volume":"71","author":"Don-Doncow","year":"2017","journal-title":"Eur Urol"},{"issue":"2","key":"2026052423113505700_bqag056-B102","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3390\/cancers6020829","article-title":"The multifaceted roles of STAT3 signaling in the progression of prostate cancer","volume":"6","author":"Bishop","year":"2014","journal-title":"Cancers (Basel)"},{"issue":"8","key":"2026052423113505700_bqag056-B103","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/onc.2015.150","article-title":"Targeting JAK kinase in solid tumors: emerging opportunities and challenges","volume":"35","author":"Buchert","year":"2016","journal-title":"Oncogene"},{"issue":"1","key":"2026052423113505700_bqag056-B104","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13046-024-02949-5","article-title":"Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery","volume":"43","author":"Hu","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"issue":"7","key":"2026052423113505700_bqag056-B105","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1084\/jem.20110283","article-title":"Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas","volume":"208","author":"Pilati","year":"2011","journal-title":"J Exp Med"},{"issue":"48","key":"2026052423113505700_bqag056-B106","doi-asserted-by":"crossref","first-page":"45443","DOI":"10.1074\/jbc.M107527200","article-title":"Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation","volume":"276","author":"Turkson","year":"2001","journal-title":"J Biol Chem"},{"issue":"12","key":"2026052423113505700_bqag056-B107","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1021\/cb7001973","article-title":"An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects","volume":"2","author":"Siddiquee","year":"2007","journal-title":"ACS Chem Biol"},{"key":"2026052423113505700_bqag056-B108","doi-asserted-by":"crossref","first-page":"836724","DOI":"10.3389\/fphar.2022.836724","article-title":"Novel STAT3 inhibitors targeting STAT3 dimerization by binding to the STAT3 SH2 domain","volume":"13","author":"Hua","year":"2022","journal-title":"Front Pharmacol"},{"issue":"18","key":"2026052423113505700_bqag056-B109","doi-asserted-by":"crossref","first-page":"26307","DOI":"10.18632\/oncotarget.8368","article-title":"Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma","volume":"7","author":"Bharadwaj","year":"2016","journal-title":"Oncotarget"},{"issue":"18","key":"2026052423113505700_bqag056-B110","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.1158\/1078-0432.CCR-16-2253","article-title":"Multifunctional effects of a small-molecule STAT3 inhibitor on NASH and hepatocellular carcinoma in mice","volume":"23","author":"Jung","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2026052423113505700_bqag056-B111","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1158\/1078-0432.CCR-24-2920","article-title":"Phase I trial of TTI-101, a first-in-class oral inhibitor of STAT3, in patients with advanced solid tumors","volume":"31","author":"Tsimberidou","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026052423113505700_bqag056-B112","doi-asserted-by":"crossref","first-page":"114688","DOI":"10.1016\/j.bcp.2021.114688","article-title":"TTI-101: a competitive inhibitor of STAT3 that spares oxidative phosphorylation and reverses mechanical allodynia in mouse models of neuropathic pain","volume":"192","author":"Kasembeli","year":"2021","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"2026052423113505700_bqag056-B113","doi-asserted-by":"crossref","first-page":"6710","DOI":"10.1038\/s41467-025-61962-0","article-title":"ATP plays a structural role in Hsp90 function","volume":"16","author":"Reidy","year":"2025","journal-title":"Nat Commun"},{"issue":"8","key":"2026052423113505700_bqag056-B114","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1016\/j.bbagen.2017.05.006","article-title":"Targeting the Hsp90 C-terminal domain to induce allosteric inhibition and selective client downregulation","volume":"1861","author":"Goode","year":"2017","journal-title":"Biochim Biophys Acta Gen Subj"},{"issue":"1","key":"2026052423113505700_bqag056-B115","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1158\/1078-0432.CCR-11-1000","article-title":"Hsp90 molecular chaperone inhibitors: are we there yet?","volume":"18","author":"Neckers","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2026052423113505700_bqag056-B116","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1186\/1471-2407-11-468","article-title":"Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells","volume":"11","author":"Eskew","year":"2011","journal-title":"BMC Cancer"},{"issue":"18","key":"2026052423113505700_bqag056-B117","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1021\/jm200553w","article-title":"Targeting the heat shock protein 90 dimer with dimeric inhibitors","volume":"54","author":"Kusuma","year":"2011","journal-title":"J Med Chem"},{"issue":"13","key":"2026052423113505700_bqag056-B118","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s40265-022-01764-6","article-title":"Pimitespib: first approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"issue":"48","key":"2026052423113505700_bqag056-B119","doi-asserted-by":"crossref","first-page":"15529","DOI":"10.1021\/ja065793p","article-title":"Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90","volume":"128","author":"Burlison","year":"2006","journal-title":"J Am Chem Soc"},{"issue":"6","key":"2026052423113505700_bqag056-B120","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1124\/mol.109.058545","article-title":"KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells","volume":"76","author":"Shelton","year":"2009","journal-title":"Mol Pharmacol"},{"issue":"21","key":"2026052423113505700_bqag056-B121","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.1021\/ol061918j","article-title":"Synthesis and evaluation of coumermycin A1 analogues that inhibit the Hsp90 protein folding machinery","volume":"8","author":"Burlison","year":"2006","journal-title":"Org Lett"},{"issue":"1","key":"2026052423113505700_bqag056-B122","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1021\/ml400404s","article-title":"Identification of a new scaffold for hsp90 C-terminal inhibition","volume":"5","author":"Zhao","year":"2014","journal-title":"ACS Med Chem Lett"},{"issue":"1","key":"2026052423113505700_bqag056-B123","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/pros.21035","article-title":"Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells","volume":"70","author":"Matthews","year":"2010","journal-title":"Prostate"},{"issue":"3","key":"2026052423113505700_bqag056-B124","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/cbdd.12176","article-title":"Inhibitors of apoptotic proteins: new targets for anticancer therapy","volume":"82","author":"Saleem","year":"2013","journal-title":"Chem Biol Drug Des"},{"issue":"2","key":"2026052423113505700_bqag056-B125","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.3390\/ijms15022494","article-title":"Survivin as a preferential target for cancer therapy","volume":"15","author":"Mobahat","year":"2014","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2026052423113505700_bqag056-B126","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/cncr.20039","article-title":"Survivin expression is associated with features of biologically aggressive prostate carcinoma","volume":"100","author":"Shariat","year":"2004","journal-title":"Cancer"},{"issue":"5","key":"2026052423113505700_bqag056-B127","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1097\/01.ju.0000120317.88372.03","article-title":"Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis","volume":"171","author":"Kishi","year":"2004","journal-title":"J Urol"},{"issue":"4","key":"2026052423113505700_bqag056-B128","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.ijrobp.2009.09.007","article-title":"Survivin is a potential mediator of prostate cancer metastasis","volume":"78","author":"Zhang","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"2026052423113505700_bqag056-B129","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/77929","article-title":"Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement","volume":"7","author":"Verdecia","year":"2000","journal-title":"Nat Struct Biol"},{"issue":"2","key":"2026052423113505700_bqag056-B130","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1158\/0008-5472.CAN-15-1874","article-title":"Effective targeting of the survivin dimerization interface with small-molecule inhibitors","volume":"76","author":"Qi","year":"2016","journal-title":"Cancer Res"},{"key":"2026052423113505700_bqag056-B131","doi-asserted-by":"crossref","first-page":"116761","DOI":"10.1016\/j.bmc.2022.116761","article-title":"A novel survivin dimerization inhibitor without a labile hydrazone linker induces spontaneous apoptosis and synergizes with docetaxel in prostate cancer cells","volume":"65","author":"Peery","year":"2022","journal-title":"Bioorg Med Chem"},{"key":"2026052423113505700_bqag056-B132","doi-asserted-by":"crossref","first-page":"108714","DOI":"10.1016\/j.bioorg.2025.108714","article-title":"Design, synthesis, and evaluation of quinoxaline-based survivin inhibitors for castration-resistant prostate cancer","volume":"163","author":"Cui","year":"2025","journal-title":"Bioorg Chem"},{"issue":"1","key":"2026052423113505700_bqag056-B133","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/aps.2014.18","article-title":"Androgen receptor: structure, role in prostate cancer and drug discovery","volume":"36","author":"Tan","year":"2015","journal-title":"Acta Pharmacol Sin"},{"issue":"12","key":"2026052423113505700_bqag056-B134","doi-asserted-by":"crossref","first-page":"e52764","DOI":"10.15252\/embr.202152764","article-title":"The androgen receptor depends on ligand-binding domain dimerization for transcriptional activation","volume":"22","author":"El Kharraz","year":"2021","journal-title":"EMBO Rep"},{"issue":"19","key":"2026052423113505700_bqag056-B135","doi-asserted-by":"crossref","first-page":"17520","DOI":"10.1021\/acs.jmedchem.4c01464","article-title":"Discovery of thiadiazoleamide derivatives as potent, selective, and orally available antagonists disrupting androgen receptor homodimer","volume":"67","author":"Liao","year":"2024","journal-title":"J Med Chem"},{"issue":"4","key":"2026052423113505700_bqag056-B136","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1021\/acscentsci.2c01548","article-title":"Small-molecule inhibition of androgen receptor dimerization as a strategy against prostate cancer","volume":"9","author":"Fu","year":"2023","journal-title":"ACS Cent Sci"},{"key":"2026052423113505700_bqag056-B137","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.canlet.2018.08.016","article-title":"Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer","volume":"437","author":"Dalal","year":"2018","journal-title":"Cancer Lett"},{"issue":"5","key":"2026052423113505700_bqag056-B138","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.3390\/ijms22052493","article-title":"Development of novel inhibitors targeting the D-box of the DNA binding domain of androgen receptor","volume":"22","author":"Radaeva","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"7","key":"2026052423113505700_bqag056-B139","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.3390\/ijms26073117","article-title":"The potential of peptide-based inhibitors in disrupting protein-protein interactions for targeted cancer therapy","volume":"26","author":"Afonso","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2026052423113505700_bqag056-B140","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1006\/jmbi.1998.2439","article-title":"The atomic structure of protein-protein recognition sites","volume":"285","author":"Lo Conte","year":"1999","journal-title":"J Mol Biol"},{"issue":"7","key":"2026052423113505700_bqag056-B141","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1039\/D4MD00202D","article-title":"Rational design of small-sized peptidomimetic inhibitors disrupting protein-protein interaction","volume":"15","author":"Wang","year":"2024","journal-title":"RSC Med Chem"},{"issue":"3","key":"2026052423113505700_bqag056-B142","doi-asserted-by":"crossref","first-page":"108282","DOI":"10.1016\/j.jbc.2025.108282","article-title":"Emerging approaches to investigating functional protein dynamics in modular redox enzymes: nitric oxide synthase as a model system","volume":"301","author":"Jiang","year":"2025","journal-title":"J Biol Chem"},{"key":"2026052423113505700_bqag056-B143","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3389\/fcell.2017.00010","article-title":"Strategies to inhibit Myc and their clinical applicability","volume":"5","author":"Whitfield","year":"2017","journal-title":"Front Cell Dev Biol"},{"issue":"10","key":"2026052423113505700_bqag056-B144","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.chembiol.2012.08.021","article-title":"Revisiting the specificity of small molecule inhibitors: the example of stattic in dendritic cells","volume":"19","author":"Sanseverino","year":"2012","journal-title":"Chem Biol"},{"issue":"2","key":"2026052423113505700_bqag056-B145","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ccell.2015.07.001","article-title":"Small molecule inhibition of ERK dimerization prevents tumorigenesis by RAS-ERK pathway oncogenes","volume":"28","author":"Herrero","year":"2015","journal-title":"Cancer Cell"},{"issue":"1","key":"2026052423113505700_bqag056-B146","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41523-023-00533-2","article-title":"Estrogen\/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive\/HER2-positive breast cancer","volume":"9","author":"Pegram","year":"2023","journal-title":"NPJ Breast Cancer"},{"issue":"4","key":"2026052423113505700_bqag056-B147","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.cell.2012.02.063","article-title":"Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization","volume":"149","author":"Shan","year":"2012","journal-title":"Cell"},{"issue":"10","key":"2026052423113505700_bqag056-B148","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1016\/j.bmc.2017.06.052","article-title":"Therapeutic peptides: historical perspectives, current development trends, and future directions","volume":"26","author":"Lau","year":"2018","journal-title":"Bioorg Med Chem"},{"issue":"6","key":"2026052423113505700_bqag056-B149","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/s12276-023-01016-x","article-title":"Peptides as multifunctional players in cancer therapy","volume":"55","author":"Vadevoo","year":"2023","journal-title":"Exp Mol Med"},{"issue":"4","key":"2026052423113505700_bqag056-B150","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3390\/cells9040883","article-title":"Blocking Myc to treat cancer: reflecting on two decades of Omomyc","volume":"9","author":"Masso-Valles","year":"2020","journal-title":"Cells"},{"issue":"9","key":"2026052423113505700_bqag056-B151","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.chembiol.2014.09.001","article-title":"Small-molecule inhibitors of protein-protein interactions: progressing toward the reality","volume":"21","author":"Arkin","year":"2014","journal-title":"Chem Biol"},{"key":"2026052423113505700_bqag056-B152","doi-asserted-by":"crossref","first-page":"116842","DOI":"10.1016\/j.ejmech.2024.116842","article-title":"Innovative medicinal chemistry strategies for enhancing drug solubility","volume":"279","author":"He","year":"2024","journal-title":"Eur J Med Chem"},{"issue":"5","key":"2026052423113505700_bqag056-B153","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3390\/ph14050449","article-title":"Heterocycles as a peptidomimetic scaffold: solid-phase synthesis strategies","volume":"14","author":"Abdildinova","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"7","key":"2026052423113505700_bqag056-B154","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1248\/cpb.c20-00017","article-title":"Bone-targeted drug delivery systems and strategies for treatment of bone metastasis","volume":"68","author":"Katsumi","year":"2020","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"2026052423113505700_bqag056-B155","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jconrel.2022.08.034","article-title":"Research progress of bone-targeted drug delivery system on metastatic bone tumors","volume":"350","author":"Hu","year":"2022","journal-title":"J Control Release"},{"issue":"1-2","key":"2026052423113505700_bqag056-B156","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1053\/j.seminoncol.2023.09.003","article-title":"PARP inhibitors for prostate cancer","volume":"51","author":"Longoria","year":"2024","journal-title":"Semin Oncol"},{"issue":"10","key":"2026052423113505700_bqag056-B157","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.3390\/ph15101283","article-title":"Strategies for improving peptide stability and delivery","volume":"15","author":"Al Musaimi","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"19","key":"2026052423113505700_bqag056-B158","doi-asserted-by":"crossref","first-page":"5236","DOI":"10.1158\/1078-0432.CCR-21-0715","article-title":"Phase 1 trial of ALRN-6924, a dual inhibitor of MDMX and MDM2, in patients with solid tumors and lymphomas bearing wild-type TP53","volume":"27","author":"Saleh","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2026052423113505700_bqag056-B159","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1021\/jacsau.3c00795","article-title":"Development of a double-stapled peptide stabilizing both alpha-Helix and beta-sheet structures for degrading transcription factor AR-V7","volume":"4","author":"Ma","year":"2024","journal-title":"JACS Au"},{"issue":"10","key":"2026052423113505700_bqag056-B160","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1039\/C7CS00877E","article-title":"Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications","volume":"47","author":"Spicer","year":"2018","journal-title":"Chem Soc Rev"},{"issue":"9","key":"2026052423113505700_bqag056-B161","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.3390\/molecules28093698","article-title":"PROTACs in the management of prostate cancer","volume":"28","author":"Yedla","year":"2023","journal-title":"Molecules"},{"issue":"4","key":"2026052423113505700_bqag056-B162","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1177\/2472555220965528","article-title":"E3 ligase ligands for PROTACs: how they were found and how to discover new ones","volume":"26","author":"Ishida","year":"2021","journal-title":"SLAS Discov"},{"issue":"3","key":"2026052423113505700_bqag056-B163","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3390\/cancers16030663","article-title":"Insight into recent advances in degrading androgen receptor for castration-resistant prostate cancer","volume":"16","author":"Chen","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2026052423113505700_bqag056-B164","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/1535-7163.MCT-20-0417","article-title":"Effects of MTX-23, a novel PROTAC of androgen receptor splice variant-7 and androgen receptor, on CRPC resistant to second-line antiandrogen therapy","volume":"20","author":"Lee","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"24","key":"2026052423113505700_bqag056-B165","doi-asserted-by":"crossref","first-page":"6071","DOI":"10.3390\/cancers14246071","article-title":"Androgen receptor signaling inhibition in advanced castration resistance prostate cancer: what is expected for the near future?","volume":"14","author":"Pozas","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2026052423113505700_bqag056-B166","doi-asserted-by":"crossref","first-page":"7133","DOI":"10.1038\/s41467-022-34807-3","article-title":"DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs","volume":"13","author":"Li","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"2026052423113505700_bqag056-B167","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1038\/s41467-018-06845-3","article-title":"Design of peptoid-peptide macrocycles to inhibit the beta-catenin TCF interaction in prostate cancer","volume":"9","author":"Schneider","year":"2018","journal-title":"Nat Commun"},{"issue":"6","key":"2026052423113505700_bqag056-B168","doi-asserted-by":"crossref","first-page":"e2322412122","DOI":"10.1073\/pnas.2322412122","article-title":"High-throughput discovery of inhibitory protein fragments with AlphaFold","volume":"122","author":"Savinov","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2026052423113505700_bqag056-B169","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1038\/s41589-025-01929-w","article-title":"Accurate de novo design of high-affinity protein-binding macrocycles using deep learning","volume":"21","author":"Rettie","year":"2025","journal-title":"Nat Chem Biol"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/endo\/advance-article-pdf\/doi\/10.1210\/endocr\/bqag056\/68223766\/bqag056.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/167\/6\/bqag056\/68223766\/bqag056.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/167\/6\/bqag056\/68223766\/bqag056.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T03:12:05Z","timestamp":1779678725000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/doi\/10.1210\/endocr\/bqag056\/8670070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":169,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5,6]]}},"URL":"https:\/\/doi.org\/10.1210\/endocr\/bqag056","relation":{},"ISSN":["1945-7170"],"issn-type":[{"value":"1945-7170","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,5]]},"article-number":"bqag056"}}